Physician profile
Jesse Bone
NPI 1770039752
$2,031.43
in general payments reported to CMS, 2019-2025
22 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $510 · 2023: $222 · 2024: $236 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $627.53 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $396.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.80 | 2021-2025 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $173.79 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $104.27 | 2021-2025 | Austedo Xr, Uzedy |
| Lilly USA, LLC | $76.15 | 2021-2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.13 | 2021-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $45.36 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.90 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $36.94 | 2021 | |
| Hologic Sales and Service, LLC | $32.65 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $31.28 | 2023 | |
| Pfizer INC. | $31.08 | 2023 | |
| Neurocrine Biosciences, INC. | $28.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.51 | 2024 | Jardiance |
| Seqirus USA INC | $16.13 | 2022 | |
| Exact Sciences Corporation | $15.50 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.30 | 2023 | |
| Glaxosmithkline, LLC. | $14.51 | 2021 | |
| Lundbeck LLC | $14.41 | 2021 | |
| Abbott Laboratories | $13.87 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.